Global Information
회사소개 | 문의 | 비교리스트

세계의 감마아미노부티르산(GABA) 수용체 시장(2021-2028년)

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - 2021-2028

리서치사 DataM Intelligence
발행일 On Demand Report 상품코드 1043595
페이지 정보 영문 180 Pages 배송안내 2일 (영업일 기준)
가격
US $ 4,350 ₩ 5,599,000 PDF & Excel (Single User License)
US $ 4,850 ₩ 6,243,000 PDF & Excel (Multiple User License)
US $ 7,850 ₩ 10,105,000 PDF & Excel (Enterprise License)


세계의 감마아미노부티르산(GABA) 수용체 시장(2021-2028년) Global Gamma-Aminobutyric Acid (GABA) Receptor Market - 2021-2028
발행일 : On Demand Report 페이지 정보 : 영문 180 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 감마아미노부티르산(GABA) 수용체(Gamma-Aminobutyric Acid (GABA) Receptor) 시장에 대해 조사했으며, 시장의 영향과 기회, 성장 촉진 및 억제요인, 부문·지역별 시장 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 세계의 감마아미노부티르산(GABA) 수용체 조사 방법과 범위

  • 조사 방법
  • 조사 목적과 조사 범위

제2장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 시장 정의와 개요

제3장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 주요 요약

  • 종류별 시장 내역
  • 의약품별 시장 내역
  • 적응증별 시장 내역
  • 지역별 시장 내역

제4장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 시장 역학

  • 시장에 영향을 미치는 요인
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석

제5장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 업계 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 파이프라인 분석
  • 가격 분석
  • 규제 분석

제6장 세계의 감마아미노부티르산(GABA) 수용체 시장 : COVID-19 분석

  • 시장의 COVID-19 분석
  • COVID-19에서의 가격 동향
  • 수요와 공급 스펙트럼
  • 팬데믹 동안 시장과 관련된 정부 정책
  • 제조업체의 전략적 이니셔티브
  • 결론

제7장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 의약품별

  • 서론
  • 벤조디아제핀
    • 로라제팜(Ativan)
    • 미다졸람(Versed)
    • 알프라졸(Xanax)
    • 디아제팜(Valium)
  • 바르비투르산염
    • 메토헥시탈(Brevital)
    • 펜토바르비탈(Nembutal)
    • 아모바비탈(Amytal)
    • 프리미돈(Mysoline)
  • 비가바트린
  • 프로포폴
  • 플루마제닐
  • 바클로펜
  • 가바펜틴
  • 졸피뎀
  • 기타

제8장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 종류별

  • 서론
  • GABAA
  • GABAB

제9장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 용도별

  • 서론
  • 알츠하이머병
  • ADHD
  • 정신장애
  • 전신 마취
  • 신경병증성 통증
  • 근이완제
  • 기타

제10장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 지역별

  • 서론
  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동과 아프리카

제11장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 경쟁 상황

  • 경쟁 시나리오
  • 주요 발전과 전략
  • 기업 점유율 분석
  • 제품 벤치마크
  • 주목해야 할 주요 기업
  • 파괴적 기술을 가진 기업

제12장 세계의 감마아미노부티르산(GABA) 수용체 시장 : 기업 개요

  • Pfizer Inc
  • Merck KGaA
  • Bausch Health US LLC
  • Lundbeck
  • Sanofi-Aventis U.S. LLC
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd
  • LGM PHARMA

제13장 세계의 감마아미노부티르산(GABA) 수용체 시장 : DataM

  • 부록
  • 당사·서비스에 대해
  • 문의
KSM 22.01.25

Market Overview

The global gamma-aminobutyric acid (GABA) receptor market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter found in the central nervous system of mammals. The neurotransmitter reduces the activity of neurons to which it binds, thus is used to control anxiety or fear when neurons are overexcited. GABA receptors are protein molecules that respond to neurotransmitter GABA.

Market Dynamics

The global gamma-aminobutyric acid (GABA) receptor market growth is driven by the rise in incidences of neurological disorders and increase in aging population, increased funding by government and private organizations across emerging economies for the treatment of neurological disorders is expected to provide growth opportunities for market growth.

Rise in incidences of neurological disorders coupled with the introduction of novel drugs are expected to drive the market growth

Increasing prevalence of epilepsy are the major driving factors of the market. For instance, According to World Health Organization (WHO) around 50 million people worldwide have epilepsy. The average incidence of epilepsy each year in the U. S is estimated at 150,000 or 48 for every 100,000 people. It was also found that in the United States, the number of males and females with Epilepsy was 1,477,323 and 1,331,276, respectively, in 2017. Benzodiazepines (BZDs) are important agents in the management of epilepsy. They are the first choice of drugs for status epilepticus and seizures associated with post-anoxic insult and are also frequently used to treat febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include they bind to the GABA-A receptor, increasing the calming effect, rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in various clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. For instance, In January 2020, the US FDA approved Neurelis, Inc drug Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in people with epilepsy six years of age and older.

Side effects associated with the GABA receptor binding drugs is likely to hamper the market growth

The most common side effects of GABA include dizziness, anxiety, drowsiness, dry mouth, balance problems, constipation, blurred vision, itchiness, irritation, stomach pain, memory problems, increased appetite, joint and muscle pain.

COVID-19 Impact Analysis

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, and confusion and behavioral disturbances. The concurrent use of treatments for COVID-19 and antipsychotics had eventual drug-drug interactions, which had a short-term negative impact on the market.

Segment Analysis

The diazepam segment is expected to hold the largest share in this market segment

Diazepam is likely to be the largest segment during the forecast period due to the new route of administration, strategic collaboration between companies for the development & commercialization of diazepam, and lower prescription cost for major diazepam factors attributed to the higher growth of the diazepam segment.

For instance, Valtoco a Neurelis, Inc product is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement to obtain outstanding absorption, tolerability, and reliability in a nasal formulation and; it is delivered via a nasal formulation in a spray, being developed to manage children and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.

Geographical Analysis

North America region holds the largest market share of global gamma-aminobutyric acid (GABA) receptor market

North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals in that region. For instance, In February 2020, United States Food and Drug Administration provided approval to Merck for its Belsomra drug in the treatment of insomnia in patients with mild-to-moderate Alzheimer's disease. An article published by the National Center for Biotechnology Information, U.S. Library of Medicine in February 2018 stated that 50,000 to 150,000 people in the U.S. suffer from status epilepticus, with mortality estimated at less than 3% in children, but up to 30% in adults. For instance, Aquestive Therapeutics collaborated with Syneos Health, Covance, in 2020 completed Phase 3 trial of safety and tolerability study of chronic intermittent use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. An increase in the development of mental healthcare services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of a generalized anxiety disorder (GAD).

Competitive Landscape

The global gamma-aminobutyric acid (GABA) receptor market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck Kagan, Bausch Health US LLC, Pfizer Inc, Lundbeck, Sanofi-Aventis U.S. LLC, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd, LGM PHARMA.

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: XANAX (ALPRAZOLAM)- XANAX is a benzodiazepine indicated for the acute treatment of generalized anxiety disorder in adults.

Why Purchase the Report?

  • Visualize the composition of the gamma-aminobutyric acid (GABA) receptor market segmentation by medications, type, indication and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in gamma-aminobutyric acid (GABA) receptor market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of gamma-aminobutyric acid (GABA) receptor market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players.

The global gamma-aminobutyric acid (GABA) receptor market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Medications

  • Benzodiazepines

Lorazepam (Ativan)

Midazolam (Versed)

Alprazolam (Xanax)

Diazepam (Valium)

  • Barbiturates

Methohexital (Brevital)

Pentobarbital (Nembutal)

Amobarbital (Amytal)

Primidone (Mysoline)

  • Vigabatrin
  • Propofol
  • Flumazenil
  • Baclofen
  • Gabapentin
  • Zolpidem
  • Others

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Type

  • GABAA
  • GABAB

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Indication

  • Attention Deficit Hyperactivity Disorder
  • Psychiatric Disorders
  • Alzheimer's Disease
  • General anesthesia
  • Neuropathic pain
  • Muscle relaxant
  • Other

Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Gamma-Aminobutyric Acid (GABA) Receptor Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Market Definition and Overview

3. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Medications
  • 3.3. Market Snippet by Indication
  • 3.4. Market Snippet by Region

4. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in incidences of neurological disorders coupled with the introduction of novel drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the GABA receptor binding drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pipeline Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Medications

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications Segment
    • 7.1.2. Market Attractiveness Index, By medications Segment
  • 7.2. Benzodiazepines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 7.2.3. Lorazepam (Ativan)
    • 7.2.4. Midazolam (Versed)
    • 7.2.5. Alprazolam (Xanax)
    • 7.2.6. Diazepam (Valium)
  • 7.3. Barbiturates
    • 7.3.1. Methohexital (Brevital)
    • 7.3.2. Pentobarbital (Nembutal)
    • 7.3.3. Amobarbital (Amytal)
    • 7.3.4. Primidone (Mysoline)
  • 7.4. Vigabatrin
  • 7.5. Propofol
  • 7.6. Flumazenil
  • 7.7. Baclofen
  • 7.8. Gabapentin
  • 7.9. Zolpidem
  • 7.10. Others

8. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. GABAA*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. GABAB

9. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Alzheimer's Disease*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Attention Deficit Hyperactivity Disorder
  • 9.4. Psychiatric Disorders
  • 9.5. General anesthesia
  • 9.6. Neuropathic pain
  • 9.7. Muscle relaxant
  • 9.8. Other

10. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Medications
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Key Developments and Strategies
  • 11.3. Company Share Analysis
  • 11.4. Product Benchmarking
  • 11.5. Key Companies to Watch
  • 11.6. Company with disruptive technology

12. Global Gamma-Aminobutyric Acid (GABA) Receptor Market- Company Profiles

  • 12.1. Pfizer Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. Bausch Health US LLC
  • 12.4. Lundbeck
  • 12.5. Sanofi-Aventis U.S. LLC
  • 12.6. Amneal Pharmaceuticals LLC
  • 12.7. Sun Pharmaceutical Industries Ltd
  • 12.8. LGM PHARMA

LIST NOT EXHAUSTIVE

13. Global Gamma-Aminobutyric Acid (GABA) Receptor Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us
Back to Top
전화 문의
F A Q